Serial Ultrasound of Solid Tumor Lesions to Detect Early Response to Cancer Immunotherapy
Stanford University
30 participants
Mar 21, 2022
INTERVENTIONAL
Conditions
Summary
Primary objective is to assess whether changes in quantitative tumor perfusion parameters after 3 weeks of treatment, as measured by CEUS, can predict initial objective response to therapy, defined by current standard-of-care Secondary objectives are to evaluate if there is an optimal ultrasound imaging modality (CEUS or conventional power Doppler or LEAD ultrasound) or optimal time point to predict initial objective response and to assess the correlation of tumor perfusion parameters with change in overall tumor burden, change in diameter on a per-lesion basis, and with 12-month progression-free survival (PFS).
Eligibility
Inclusion Criteria6
- years of age or older
- at least one solid tumor lesion greater than 1 cm in diameter (primary tumor and/or at metastatic site), amenable to ultrasound imaging
- planned to be treated with ICI therapy (single agent or in combination with any other drug)
- written informed consent.
- prior use of any ICI is not necessarily excluded, and patients may be included with the approval of the Protocol Director
- Subjects may participate in the study more than once at the discretion of the Protocol Director, for example, if they receive different lines of treatment that all qualify for the study.
Exclusion Criteria3
- known hypersensitivity to sulfur hexafluoride lipid microsphere or its components, such as polyethylene glycol (PEG)
- any comorbid condition that, in the opinion of the treating provider or the Protocol Directors, compromises the participant's ability to participate in the study
- Examples: any mental condition that compromises the ability to follow a consent discussion, or to make informed decisions (except if represented by a Legally Authorized Representative \[LAR\]), or to have ultrasound exams.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Power Doppler measurements will be made using a portable Siemens S2000 or S3000 ultrasound scanner
Long Ensemble Angular-coherence Doppler measurements will be made using a Verasonics Vantage 256 scanner
Contrast-enhanced ultrasound measurements will be made using Lumason IV contrast injection followed by an injection of normal saline
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05206942